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Abstract
Background: Bladder cancer, the 5
th most common malignancy in the USA, is often detected as a result of
incidental findings or by presenting hematuria. Once diagnosed the disease is one of the costliest cancers to treat
due to frequent, invasive and often lifelong follow-up procedures. Because cells are shed into urine, there has been
an emerging effort to develop non-invasive tests for the detection of bladder cancer. Expression of survivin, a
member of the inhibitor of apoptosis protein family, has been associated with bladder cancer. Therefore, the goal
of this study was to determine the feasibility of transducing viable exfoliated cells obtained from urine with an
adenoviral vector in which a reporter gene is under the control of the survivin promoter.
Methods: Exfoliated cells from urine were obtained from 36 human subjects (> 40 years old). An adenovirus in
which GFP expression is under control of the survivin promoter (Ad.Surv.GFP) was generated. An adenovirus in
which GFP is expressed from the CMV promoter served as a control. GFP expression was analyzed by fluorescent
microscopy and quantified by flow cytometry.
Results: Short-term cultures from exfoliated cells in urine could be established in 16 of 31 samples. These cultures
were successfully transduced with Ad.CMV.GFP. Analysis of GFP expression following transduction with Ad.Surv.GFP,
indicated that the survivin promoter was preferentially active in UM-UC-3 bladder cancer cells compared to non-
malignant UROtsa cells. Interestingly, baseline levels of GFP expression in cultures from exfoliated cells in urine
exhibited higher baseline levels than UROtsa following transduction with Ad.Surv.GFP.
Conclusions: We demonstrated the feasibility of establishing and analysing short-term cultures isolated from
exfoliated cells in voided urine by means of adenoviral transduction, thereby forming the foundation for future
studies to determine the specificity and sensitivity of a non-invasive test based on survivin promoter activity.
Background
According to the American Cancer Society bladder can-
cer is the 5th highest in estimated new cases of cancers
by site with 14,680 bladder cancer deaths and 70,530
new diagnoses in 2010 [1,2]. Bladder cancer can be cate-
gorized into non-muscle-invasive bladder cancer or
muscle-invasive bladder cancer where 80% of the newly
diagnosed cancers are non-muscle-invasive bladder can-
cer. Unfortunately, 70% of the patients will have recur-
rence of the disease and 10-30% will progress to
muscle-invasive disease. Bladder cancer is detected as a
result of incidental findings or by presenting hematuria.
While hematuria is associated with benign conditions
such as urinary tract infections and urolithiasis, 10% of
the patients with gross hematuria are diagnosed with
bladder cancer [3]. Contrary to these statistics, microhe-
maturia is detected in 9 to 18% of normal individuals
and 2-5% of patients with microscopic hematuria are
diagnosed with bladder cancer. These findings support
the need for non-invasive methods to detect bladder
cancer prior to the onset of clinical symptoms.
Currently, fluorescence in situ hybridization (FISH),
cystoscopy and cytology are methods used for bladder
cancer surveillance in clinical practice. Patients diag-
nosed with non-invasive bladder cancer are subjected to
repeat cystoscopy and cytology every 3 months for a
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severe discomfort and morbidity of patients, resulting in
poor patient compliance. Moreover, cystoscopy can miss
the diagnosis of flat tumors or carcinoma-in-situ (CIS)
leading to 10-30% false-negative results [4]. Based on
recent cost-effectiveness studies, overall specificity for
common urine-based tumor markers (bladder tumor
antigen and nuclear matrix protein 22) was 73% to 90%
and sensitivity was 49% to 77% [5]. The majority of
bladder cancers is detected at an early stage and is
treated by surgical resection followed by intravesical
immunotherapy with Bacille Calmette-Guerin (BCG)
occasionally in combination with interferon-a2b. How-
ever, response to BCG therapy is variable. While BCG
therapy is the best available treatment, it can be limited
by severe side effects, which results in early termination
of treatment and reduced efficacy. The paucity of urine
markers of bladder cancer with high specificity and sen-
sitivity warrants identification of non-invasive screening
methods for early detection and prognosis of bladder
cancer.
Although to date, several markers of bladder cancer
have been reported, such as nuclear matrix protein 22,
hyaluronic acid, hyaluronidase and nuclear matrix pro-
teins, these markers are ineffective in reducing the number
of surveillance cystoscopies due to limited sensitivity and
specificity [6]. Survivin is a member of the inhibitor of
apoptosis protein (IAP) family and has been identified as a
potential marker for detecting high-grade urothelial blad-
der cancer with 83% sensitivity and 88% specificity [7].
Cancer cells have the ability to evade apoptosis by up-reg-
ulating IAPs such as survivin and recent evidence suggests
t h a tu r i n es u r v i v i nc a nb eu s e da sad i a g n o s t i ct e s tf o r
bladder cancer [8]. Moreover, measurement of mRNA
levels suggests that the survivin promoter is active in
malignant cells. An adenovirus in which a luciferase repor-
ter is under control of the survivin promoter has been
generated [9]. Taken together, promoter strength and the
cancer-specificity of survivin indicate the possibility to uti-
lize a survivin-driven reporter gene such as GFP (green
fluorescent protein) to detect cancer cells among exfo-
liated cells in urine. This study demonstrates feasibility of
analyzing short-term explant cultures isolated from voided
urine by means of adenovirus transduction.
Methods
Patients and samples
The study protocol was approved by the Institutional
Review Board at the Medical University of South Caro-
lina and all patients signed a written consent form
before initiation of study participation. Urine samples
were obtained by spontaneous micturition from patients
with a history of bladder cancer, suspected bladder can-
cer (hematuria), and volunteers without suspected or
confirmed bladder cancer. Eligible patients were >40
years old and had to be free of urinary tract infections
at the time of study participation.
Short-term explant cell cultures
Briefly, urine was collected in a sterile container and centri-
fuged at 200 x g for 10 min at 22°C. The cell pellet was
washed with warm RPMI1640 medium containing 10%
fetal bovine serum and centrifuged again at 200 x g. Pellets
were resuspended in 4 ml RPMI1640 containing 1% anti-
biotic-antimycotic solution (Gibco), 1:1000 Primocin (Invi-
voGen, San Diego, CA) and 20% FBS and were equally
divided into 4 wells of a 24-well tissue culture plate (Corn-
ing). Plates were incubated at 37°C, 5% CO2. Photographs
were taken on day 0, on day 3 after media was refreshed
and on day 10, when each well was examined for growth.
If no growth was observed in any of the 4 wells on day 10,
the sample was recorded as “no growth”. Outgrowth into a
few patches of cells was categorized as “minimal growth”
whereas growth throughout the well (sub-confluent or
confluent) was categorized as “sufficient outgrowth”.
Cell lines and Cell culture
UM-UC-3 cells were purchased from the American
Type Culture Collection (Rockville, MD) and maintained
in RPMI1640 medium (Gibco/Invitrogen, Carlsbad, CA)
supplemented with heat-inactivated 10% fetal bovine
serum (Hyclone, Logan, UT). The UROtsa cell line,
kindly provided by Dr. Donald Sens (University of
North Dakota, Grand Forks, ND) was derived from nor-
mal human urothelial cells and immortalized with the
SV40 T-antigen [10]. UROtsa cells were maintained in
DMEM medium containing 2 mg/ml glucose and 5%
FBS. Cell cultures were maintained at 37°C in a 5% CO2
atmosphere (Falcon, Bedford, MA).
Construction of Ad.Surv.GFP
Dr. Semyon Rubinchik, at the Medical University of South
Carolina, generously provided plasmid pShuttle-C.mcs.B.
The Sp1 plasmid containing the full-length survivin gene
promoter was generously provided by Dr. Maureen Mur-
phy (Fox Chase Cancer Center, Philadelphia, PA) [11]. The
pEGFP-C1 plasmid was obtained from Clontech (Moun-
tain View, CA) and was the source of the EGFP gene. Ad.
Surv.GFP virus was constructed by ligating the SpeI-Xba1
fragment from Sp1 and the Nhe1-Mlu1 fragment of
pEGFP-C1 to form a product with Spe1 and Mlu1 ends.
This product was ligated into pShuttle-C.mcs.B digested
with MluI and Spe1 to create a shuttle plasmid compatible
with the AdEASY adenovirus production system. The
completed shuttle plasmid was linearized with PmeI and
transformed into competent BJ5183 E. coli. Recombinant
AdEASY plasmids were purified and transformed into 293
cells to produce virus as previously described [12].
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For short-term explant cultures, wells with sufficient
growth from a single donor were photographed, trypsi-
nized, combined and redistributed evenly into 3 wells of
a 24-well plate. 24 hours later, wells either remained
uninfected or were infected with 2 × 10
6 IU of virus Ad.
CMV-GFP (control) or Ad.Surv.GFP in 1 ml medium.
UM-UC-3 and UROtsa cells were plated and infected in
parallel at 2 × 10
4 cells per well for an approximate
multiplicity of infection of 100. Photographs were taken
at 24 hours and 72 hours post infection with 10× objec-
tive and at 1.5 sec. exposure for fluorescence. UROtsa
and UM-UC-3 cells, infected with Ad.CMV.GFP or Ad.
Surv.GFP, were also analyzed for GFP. For quantifica-
tion of GFP-positive cells, wells were trypsinized, cells
pelleted and fixed in 3.7% formalin. GFP expression was
quantified by the MUSC flow cytometry core facility
using a FACSCalibur (BD) and Cell Quest software.
Results
Short-term explant culture of exfoliated cells from voided
urine
Initially 22 voided urine samples were used to optimize
parameters for outgrowth and to determine viral infec-
tivity. Samples were from healthy volunteers (no history
of bladder cancer or suspected bladder cancer),
suspected bladder cancer (presence of hematuria) and
history of bladder cancer. Two samples had less than
15 ml volume and three were accidentally stored at 4°C,
leading to exclusion from further analysis. Among the
remaining samples about half showed evidence of
growth (9 of 17, 53%). Microscopic appearance of three
representative samples having no growth, minimal
growth and sufficient growth is shown in Figure 1.
Exfoliated cells from urine can be transduced with
adenovirus
Transfection of primary cells is generally inefficient and
therefore the feasibility of adenoviral-driven reporter
gene expression was tested. Two urine short-term
explant cultures were exposed to an adenovirus in which
a GFP reporter gene is expressed under the control of
the CMV promoter. Images captured at 24 hours post-
infection demonstrated bright green fluorescence in vir-
tually all cells, indicating that viable, exfoliated cells from
urine can be transduced with adenovirus (Figure 2).
The survivin promoter preferentially drives GFP
expression in UM-UC-3 bladder cancer cells when
compared to UROtsa cells
Having shown that exfoliated cells from voided urine
can be used to establish short-term cultures and that
these cultures can be efficiently transduced with adeno-
virus, we generated an adenovirus in which GFP
expression was under control of the survivin promoter.
GFP expression following Ad.Surv.GFP transduction was
quantified in non-malignant UROtsa bladder epithelial
cells and the UM-UC-3 bladder cancer cell line. Ad.
CMV.GFP served as a control for infectivity. Cells were
transduced with Ad.CMV-GFP or Ad.Surv.GFP and
GFP expression quantified by flow cytometry at
72 hours post-infection. As shown in Figure 3A, the cell
lines transduced with adenovirus equally well. Only a
fraction of UM-UC-3 cells were GFP positive when
infected with Ad.Surv.GFP indicating that the survivin
promoter is substantially weaker than the CMV promo-
ter. Nevertheless, based on GFP expression, the survivin
promoter was more active in the UM-UC-3 cancer cell
line than in the non-malignant UROtsa cell line (Figure
3B, p = 0.0004).
Urine exfoliated short-term explant cultures exhibit
higher baseline levels of GFP expression than UROtsa
cells when infected with Ad.Surv.GFP
Next, 14 additional samples collected from healthy
volunteers were analyzed for outgrowth and the ability
to express GFP from the survivin promoter. Seven sam-
ples (50%) displayed growth and of these five had suffi-
cient growth to evaluate viral reporter gene expression
following infection with Ad.CMV.GFP or Ad.Surv.GFP.
Samples were evaluated in two separate experiments,
each including UROtsa and UM-UC-3 as controls. All
of the samples were efficiently transduced with Ad.
CMV.GFP (Figure 4A). When transduced with Ad.Surv.
GFP, UROtsa cells used as a negative control displayed
less than 1% GFP positive cells, whereas approximately
15% of UM-UC-3 cells were positive (Figure 4B). Inter-
estingly, the urine exfoliated short-term explant cultures
expressed survivin-driven GFP with an efficiency that
was similar or higher than UM-UC-3 cells (Figure 4B).
Discussion
Bladder cancer has a recurrence rate of up to 70%
necessitating patients with a history of bladder cancer to
undergo years if not lifetime surveillance via periodic
cystoscopy, which significantly burdens the healthcare
system [13]. There is also no reliable screening test for
early detection of bladder cancer. Urinary biomarkers
are an active area of investigation and current molecular
cytologic tests include ImmunoCyt, which detects the
glycosylated form of CEA and mucin glycoproteins
(median sensitivity of 81%; median specificity of 75%),
DD23 (Median sensitivity of 81%; median specificity of
60%), Lewis X antigen (median sensitivity of 84%; med-
ian specificity of 80%), and UroVysion test used to
detect aneuploidy for chromosomes 3, 7, 17 and loss of
9p21 locus (median sensitivity of 73%; median specificity
of 90%) [14]. Recently, fibroblast growth factor receptor
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Page 3 of 8Figure 1 Photomicrographs of exfoliated cells grown from human urine. Urine sediments collected from fresh human urine by
centrifugation were plated in complete tissue culture medium. Photomicrographs of samples from three donors are shown, taken immediately
after plating (Day 0) and 10 days later (Day 10) after a medium change on day 3. (Original magnification, 100X).
Figure 2 Adenovirus infection of primary cells grown from exfoliated cells in urine. Day 16 after plating of urine sediments from two
donors, dividing cells were infected with an adenoviral vector expressing green fluorescent protein under control of a cytomegalovirus
promoter. Each well of cells was exposed to 2 × 10
6IU of virus at a concentration of 2 × 10
6 IU/ml (Original magnification, 200X).
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tant recurrences of low-grade non-muscle-invasive blad-
der cancer with a sensitivity of 58% [15]. While it is
apparent that different molecular bladder tumor mar-
kers and clinical tests exist to detect bladder cancer
[16], these tests do not preclude the recommended inva-
sive and frequent surveillance urethrocystoscopies. Here,
we have examined the feasibility of screening short-term
explant cultures from voided urine with an adenoviral
reporter construct.
A total of 31 samples were evaluated for the ability to
grow short-term explant cultures from voided urine. In
agreement with a recent study we found that cell attach-
ment and propagation occurred within 10 days after cul-
ture initiation [17]. About half of all samples (16/31)
showed evidence of in vitro growth. This included 4/6
samples from patients with a previous history of bladder
cancer (all white males with a median age of 69.5, 72.7
+ / -1 0 . 4 ) ,4 / 5s a m p l e sf r o mp a t i e n t sp r e s e n t i n gw i t h
hematuria (1 WF, 2BF, 1WM, 1BM, median age 64, 60.8
+/- 14.7) and 8/20 healthy volunteers (8WM, 2BM,
10WF, 1AF, median age 52.5, 52.9+/- 9). In a previous
study, primary culture outgrowth from urine, defined as
the presence of islet-like cells, was observed in 54.7% of
healthy volunteers and in 86.6% of bladder cancer
patients [18]. Since none of our samples were from
patients currently having bladder cancer, our rate of
52% outgrowth is similar to the previously observed
54.7%. Upon closer examination however, the outgrowth
rate from healthy volunteers approached 90% (7/8) in
samples that were processed within 30 minutes of urine
collection. These results suggest that a short time to
processing is a critical factor to successfully establish
short-term cultures from voided urine.
Our results also demonstrate that exfoliated cells
obtained from spontaneous micturition can be trans-
duced with adenoviral reporter vectors, which provides
a novel opportunity to detect malignant cells via a non-
invasive screening modality. Survivin, a member of the
inhibitor of apoptosis family of proteins involved in reg-
ulating cell division and apoptosis, is overexpressed in
tumor cells relative to normal cells. Therefore, the survi-
vin-promoter has been used to transcriptionally target
tumors for gene therapy [9], including delivery of
adenovirus-based vectors and conditionally replicative
adenoviruses in treating malignant gliomas [19,20].
Figure 3 Transgene expression under survivin and cytomegalovirus promoters in UM-UC-3 bladder carcinoma and UROtsa cell lines.
50% confluent UM-UC-3 and UROtsa cells (2 × 10
4 cells/well) were infected in a 1 ml volume with 6 × 10
5 IU of (A) Ad.CMV.GFP or (B) Ad.Surv.
GFP, and analyzed for GFP expression 72 h after infection by flow cytometry. Ad.Surv.GFP expression was corrected for infectivity relative to UM-
UC-3 cells, determined for each experiment by Ad.CMV.GFP results. Data shown are the mean ± SD from three independent experiments. P-
value was calculated by the student t test.
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ity and 95% specificity [21], suggesting the survivin pro-
moter is preferentially activated in bladder cancer cells. In
this study we used the full-length survivin promoter to
drive GFP reporter gene expression in normal and malig-
nant bladder cancer cells. Non-malignant UROtsa and
malignant UM-UC-3 bladder cells were used to test the
survivin-driven reporter gene expression. As expected,
CMV-driven GFP expression was similar between the cell
lines whereas survivin-driven GFP expression was preferen-
tially observed in the malignant UM-UC-3 cells (Figure 3).
However, when short-term explant cultures obtained
from urine of healthy volunteers were infected with Ad.
Surv.GFP, the percentage of GFP positive cells was com-
parable to the UM-UC-3 positive control rather than the
non-malignant UROtsa cells, which served as a negative
control (Figure 4). There are several possible explana-
tions for this observation. Survivin has dual roles in reg-
ulation of G1/S transition and apoptosis protection [22].
Thus one possibility is that the level of survivin promo-
ter activity in the explant cultures is dictated by prolif-
eration and progression through the cell cycle. However,
we did not observe the growth of explant cultures to be
more rapid than UROtsa cells, which would argue
against proliferation as a cause for higher GFP expres-
sion following Ad.Surv.GFP expression. While it has
been widely accepted that survivin is expressed at low
levels, if at all, in normal differentiated tissues, there are
also reports of survivin expression in normal breast tis-
sue and fibroadenomas [23]. Weikert et al. have shown
Figure 4 Transgene expression under survivin and cytomegalovirus promoters in exfoliated cells from urine. Cell outgrowth from 5
urine samples from healthy controls were infected in two separate experiments with 2 × 10
6 IU of virus (A) Ad.CMV.GFP or (B) Ad.Surv.GFP in 1
ml medium, and analyzed for GFP expression 72 h later by flow cytometry. UM-UC-3 and UROtsa cells were included in parallel in each
experiment as controls. Left panels show the raw data from the two experiments, while right panels show the mean ± SD of the three groups.
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tumors as well as in human normal cells of the testes
[24]. These studies suggest that baselines of survivin
expression and/or promoter activity have to be estab-
lished for each cell line or primary culture. Thus our
data may indicate that primary cultures established from
voided urine simply exhibit a higher basal level of survi-
vin promoter activity than established bladder cell lines.
Conclusions
In conclusion, our study demonstrates that short-term
explant cultures can be established from at least half of
spontaneously voided urine samples and at higher rates
if processing time does not exceed 30 minutes. Suffi-
cient cells can be obtained for adenoviral transduction
and quantification of GFP reporter activity by flow cyto-
metry. Our feasibility study is limited by the subject
population, necessitating a future larger study to deter-
mine baseline level of Ad.Surv.GFP expression in
explant cultures from healthy volunteers. In addition,
spontaneously voided urine from patients with bladder
cancer will need to be included to determine specificity
and sensitivity of the non-invasive Ad.Surv.GFP test.
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